The Latest Cardiac and Vascular News
FORT MILL, S.C., Feb. 06, 2025 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (VTAK – NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 13th International Symposium on Left Atrial Appendage (ISLAA). ISLAA will take place on February 7th and 8th, 2025 in Austin, Texas.
“Revolutionary portable device leverages advanced magnetic resonance technology to rapidly detect acute stroke biomarkers, enabling frontline care teams to make faster, life-saving decisions within the critical ‘golden hour.” A Melbourne hospital images the first patient in Australia…
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX) reported 12 month data from the Phase 2 study (SYCAMORE) of REC-994, the first industry sponsored Phase 2 trial completed in Cerebral Cavernous Malformations (CCM). The Company announced in September 2024 that the signal-finding study met its primary endpoint.
SAN MATEO, Calif.–(BUSINESS WIRE)–The numbers speak for themselves, RapidAI’s deep clinical AI is delivering results where competitors are falling short. New data from the largest head-to-head study to date proves RapidAI’s LVO detection outperforms Viz.ai by a staggering 33%, detecting far more stroke cases and reducing the risk of missed […]
Centers Celebrates Target: BP™ During Heart Month; Hosts Jumping Jacks Challenge Across Facilities BRONX, N.Y., Feb. 5, 2025 /PRNewswire/ — Centers Health Care, the largest and most complete post-acute health care continuum in the Northeast that touches one million lives each year with…
Lowering of infarct growth – brain tissue loss – by 50% in patients treated in less than 12 hours following last known well Lowering of infarct growth correlated with clinically meaningful improvements in several functional stroke measures that evaluate a patient’s recovery TACOMA, Wash.,…
Dr. Ronald Benitez to present Vivistim safety and outcomes data for the largest cohort of ischemic stroke survivors AUSTIN, Texas and LOS ANGELES, Feb. 5, 2025 /PRNewswire/ — Dr. Ronald P. Benitez, a neurosurgeon at Atlantic Brain and Spine, will present safety and outcomes data from the…
OKLAHOMA CITY, Feb. 5, 2025 /PRNewswire/ — Acarix, a pioneer in the development of groundbreaking acoustic-based cardiac diagnostic solutions, is proud to announce a new strategic partnership with Geo-Med, LLC, a renowned Service-Disabled Veteran-Owned Small Business that specializes in…
Terumo Neuro Also Features Much-Anticipated SOFIA™ 88 Neurovascular Support Catheter Showcased at ISC Symposium led by Dr. Ameer E. Hassan on Thursday, February 6th ALISO VIEJO, Calif. and LOS ANGELES, Feb. 5, 2025 /PRNewswire/ — Terumo Neuro, a global neurovascular company and wholly…
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) — E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, metabolic, and kidney diseases, today announced that it has dosed its first patient in a Phase 2 clinical trial of Modified Atrial Natriuretic Peptide (MANP) for the treatment of Resistant Hypertension (BOLD-HTN). MANP was originally discovered by John C. Burnett Jr., MD, Director of the Cardiorenal Research Laboratory at Mayo Clinic. E-Star and Mayo Clinic entered into a worldwide exclusive license agreement for the development of MANP in cardiovascular and metabolic indications in 2021. With the support of $36 million in grants and seed-stage private investment, MANP has demonstrated a strong safety profile in multiple Phase 1 studies of participants with hypertension, resistant hypertension, and hypertension with comorbid cardiometabolic syndrome. Jesse Crowne, Chief Executive Officer of E-Star Biotech commented, “We are thrilled to have now dosed the first patient in our phase 2 study of MANP, the BOLD-HTN Study, which is a randomized, placebo-controlled, double-blind, multi-center Phase 2 study to evaluate the safety and efficacy of MANP in participants with Resistant Hypertension. This is the first step towards fully enrolling the study later this year, and finding new treatment pathways for patients with resistant hypertension.” An estimated 1.28 billion adults aged 30-79 years old suffer from hypertension worldwide. While scores of drugs are available to treat hypertension, only 1 in 5 adults (approximately 21%) with hypertension gain control of their condition. Hypertension remains a leading driver of premature death in both developed and developing countries. E-Star is dedicated to bringing the remaining 79% of hypertension patients under control and reducing the burden of premature death. About E-Star BioTech, LLC E-Star is developing a platform of Natriuretic Peptides for the treatment of metabolic syndrome. The Company’s lead asset, MANP, is currently being investigated in a Phase 2 clinical trial. To learn more, please visit: https://www.e-star.bio/. About Mayo ClinicMayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news. Contact: LR AdvisorsJason Assad678-570-6791
